The CCTN was established in 1996 to support research on male and female contraception and to conduct clinical trials of new contraceptive drugs and devices.
The Network is funded through the NICHD
Contraception Research Branch (CRB) and includes 19 sites for clinical evaluation of new female contraceptives and two sites for male contraceptives. Sites are located at university research centers and medical centers across the country. Each site employs a qualified obstetrician/gynecologist (for female-focused sites) or andrologist/urologist (for male-focused sites), study coordinator, and data/research manager, and has access to clinical facilities capable of recruiting for and conducting phase I, II, and III clinical trials.
The Network is funded through contracts and utilizes a Scientific Advisory Committee to advise on research topics and directions. The Scientific Advisory Committee is composed of outside experts in the fields of basic and clinical contraceptive research, pharmacology, and epidemiology. The Network also relies on a Statistical and Clinical Coordinating Center to monitor trials and coordinate data from all of its studies.
The CCTN clinical field centers are selected on the basis of their capacity to conduct Phase I, II, and III trials of oral, vaginal, intrauterine, injectable, implantable, or topical contraceptive drugs and devices.
Selected research topics include (but are not limited to):
- Studies of the ability of progestin- and testosterone-based topical gels to reduce gonadotropin levels and reversibly inhibit sperm production (spermatogenesis)
- Studies of a progesterone receptor modulator, CDB-2914, as an emergency oral contraceptive when taken within 72 hours of unprotected intercourse
- Studies of the efficacy of a novel female condom for preventing both pregnancy and sexually transmitted infections
- Studies of progestin-based compounds that can prevent pregnancy without increasing the risk of blood clots and other venous thromboembolism-type conditions, especially in obese women
- Studies of the use of a novel progestin- and estradiol-releasing vaginal ring for effective contraception without increasing the risk of blood clots and other venous thromboembolism-type conditions, especially in obese women
- California Family Health Council
- Case Western Reserve University
- Columbia University
- Eastern Virginia Medical School
- Johns Hopkins University
- Los Angeles Biomedical Research Institute/University of California, Los Angeles, Medical Center (male-focused)
- Magee—Women's Research Institute and Foundation/University of Pittsburgh Medical Center
- New York University School of Medicine
- Oregon Health Sciences University
- University of Cincinnati
- University of Colorado
- University of Pennsylvania
- University of Texas Southwestern Medical Center
- University of Chicago
- Women and Infants Hospital of Rhode island
- Boston University
- University of Utah
- Planned Parenthood Federation of America
- University of California, San Francisco
- University of California, Davis
- Los Angeles Biomedical Research Institute/University of California, Los Angeles, Medical Center (male focused)
- University of Washington (male-focused)
Health Decisions, Inc., serves as the Statistical and Clinical Coordinating Center for the CCTN.